Research from Jan 2018 validates Biotrons claims, page-6

  1. 1,085 Posts.
    lightbulb Created with Sketch. 375
    DYOR more then 7 hours


    The trial was designed to assess the safety and antiviral activity of three month’s dosing of BIT225 in combination with antiretroviral drugs in treatment-naïve HIV-positive subjects. This was a double-blind, placebo-controlled study undertaken at trial sites in Thailand. A total of 27 HIV-infected subjects, who had not previously taken any antiretroviral drugs, took once daily doses of 200 mg BIT225 or placebo for 12 weeks in combination with antiretroviral drugs. At the end of 12 weeks, all continued to take antiretroviral drugs as per standard protocols. A smaller cohort of 9 subjects took once daily doses of 100 mg BIT225 or placebo; this cohort was set up for detailed pharmacokinetic profiling of the BIT225 and its interactions with antiretroviral drugs.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.2¢
Change
0.000(0.00%)
Mkt cap ! $2.654M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
53 33177604 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 16833992 23
View Market Depth
Last trade - 16.21pm 08/07/2025 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.